- Home
- VRTX vs INFY Comparison
VRTX vs INFY Comparison
Compare VRTX & INFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRTX
- INFY
- Stock Information
- Founded
- VRTX 1989
- INFY 1981
- Country
- VRTX United States
- INFY India
- Employees
- VRTX N/A
- INFY N/A
- Industry
- VRTX EDP Services
- INFY EDP Services
- Sector
- VRTX Technology
- INFY Technology
- Exchange
- VRTX Nasdaq
- INFY Nasdaq
- Market Cap
- VRTX 119.6B
- INFY 96.0B
- IPO Year
- VRTX 1991
- INFY 1999
- Fundamental
- Price
- VRTX $396.64
- INFY $23.41
- Analyst Decision
- VRTX Buy
- INFY Hold
- Analyst Count
- VRTX 30
- INFY 8
- Target Price
- VRTX $519.12
- INFY $20.22
- AVG Volume (30 Days)
- VRTX 1.5M
- INFY 6.7M
- Earning Date
- VRTX 02-03-2025
- INFY 01-09-2025
- Dividend Yield
- VRTX N/A
- INFY 2.49%
- EPS Growth
- VRTX N/A
- INFY 5.91
- EPS
- VRTX N/A
- INFY 0.77
- Revenue
- VRTX $10,625,800,000.00
- INFY $18,836,000,000.00
- Revenue This Year
- VRTX $12.54
- INFY $3.41
- Revenue Next Year
- VRTX $8.52
- INFY $9.23
- P/E Ratio
- VRTX N/A
- INFY $29.30
- Revenue Growth
- VRTX 10.06
- INFY 1.56
- 52 Week Low
- VRTX $378.00
- INFY $16.04
- 52 Week High
- VRTX $519.88
- INFY $23.63
- Technical
- Relative Strength Index (RSI)
- VRTX 23.70
- INFY 60.06
- Support Level
- VRTX $459.79
- INFY $22.62
- Resistance Level
- VRTX $474.19
- INFY $23.63
- Average True Range (ATR)
- VRTX 12.03
- INFY 0.36
- MACD
- VRTX -4.30
- INFY 0.01
- Stochastic Oscillator
- VRTX 18.93
- INFY 86.42
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About INFY Infosys Limited
Infosys is a leading global IT services provider, with nearly 250,000 employees. Based in Bangalore, the Indian IT services firm leverages its offshore outsourcing model to derive 60% of its revenue from North America. The company offers traditional IT services offerings: consulting, managed services and cloud infrastructure services, and business process outsourcing as a service (BPaaS).